Arkansas Urology, the state’s largest and most innovative urology practice, is using a new radioactive diagnostic agent, Illuccix®, that offers more precise detection of prostate cancer treatment planning and targeted care. Arkansas Urology is the first in the state and among the first in the country to offer this tool.
“This new, innovative technology allows us to detect small prostate tumors, where other types of scans might miss them, and it provides more accurate information regarding the spread and location of the cancer,” said Dr. Kevin Claybrook, president of Arkansas Urology. “We’re proud to be the first urologists in the state to offer this new imaging agent that will help our doctors in developing individual treatment plans and improve the level of care for our patients.”
Illuccix® is the first commercially available imaging agent for 68Ga-based PSMA-targeted PET scans. In fact, the first commercial dose of Illuccix® in the United States was administered on Thursday, April 14, in Indianapolis. The first commercial dose in Arkansas was administered on Tuesday, April 19 at Arkansas Urology.
Illuccix® is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in patients with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
“We are dedicated to providing the highest level of care for our patients, and that means early and accurate detection,” said E. Scot Davis, chief executive officer of Arkansas Urology. “Illuccix®gives patients considerably improved access to PSMA-PET imaging, an advanced diagnostic tool. Arkansas Urology is a proven leader in prostate cancer prevention and treatment, and we are proud to be among the first in the country to offer this new, innovative technology.”
Illuccix® was approved in December by the U.S. Food and Drug Administration for use in patients with suspected metastasis who are candidates for treatment and those with suspected recurrence based on elevated serum prostate-specific antigen level.
Prostate cancer is the second most common cancer for men. An estimated 268,000 men will be diagnosed this year in the U.S., and 35,000 will die from the disease, according to the American Cancer Society.
For more information about Arkansas Urology’s innovative cancer treatment options, visit ArkansasUrology.com.
About Arkansas Urology
Arkansas Urology provides the latest innovations in medical technology and surgical techniques to patients through its Centers of Excellence in urological specialties. The physicians and professional staff comprise one of the most experienced and respected urological practices in the country. Arkansas Urology treats approximately 110,000 patients a year in Little Rock, North Little Rock, Benton, Conway, El Dorado, Heber Springs, Harrison, Monticello, Pine Bluff, Stuttgart, Russellville, Fayetteville, Bentonville, and Jonesboro. Arkansas Urology is made up of 19 physicians, more than 21 advanced practice providers, and more than 300 clinical and business staff employees.
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland and the United States. Its U.S. office is located in Indianapolis.
